Advertisement

Clinically Important Effects in New Drug Development

  • Kanae TogoEmail author
  • Nobushige Matsuoka
  • Satoshi Hashigaki
  • Keiji Imai
  • Takashi Moriya
Drug Information

Abstract

In new drug development, demonstrating a clinically important effect of the new drug is a key element of efficacy evaluations instead of simply showing a statistical significance. However, approaches to demonstrate clinically important effects are unclear and not well recognized among many investigators and sponsors. The minimal clinically important change from baseline (MCIC) and minimal clinically important difference between groups (MCID) are used to assess the clinically important effect.

We state the roles of MCIC and MCID in each phase of new drug development and common approaches to establishing MCIC and MCID. Furthermore, we provide some common approaches on how to practically compare the clinical trial results with the MCIC and MCID and interpret the clinical importance from applications in new drug development. We also suggest incorporating the clinical importance at the planning phase of trials.

Key Words

Clinically important effect Minimum clinically important change Minimum clinically important difference Clinical meaningfulness Drug effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shih WJ. Sample size re-estimation journey for a decade. Stat Med. 2001;20:515–518.CrossRefGoogle Scholar
  2. 2.
    Hung HMJ, Wang SJ, O’Neill RT. Methodological issues with adaptation of clinical trial design. Pharm Stat. 2006;5:99–107.CrossRefGoogle Scholar
  3. 3.
    D’Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues the encounters of academic consultants in statistics. Stat Med. 2003;22:169–186.CrossRefGoogle Scholar
  4. 4.
    Jacobson NS, Truax P. Clinical signifcance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–19.CrossRefGoogle Scholar
  5. 5.
    Cartwright ME, Cohen S, Fleishaker JC, et al. Proof of concept: a PhRMA position paper with recommendations for best practice. Clin Pharmacol Ther. 2010;87(3):278–285.CrossRefGoogle Scholar
  6. 6.
    Chow SC, Liu J P. Design and Analysis of Clinical Trials: Concepts and Methodologies, 2nd ed. New York: Wiley; 2004:438–439.Google Scholar
  7. 7.
    Golub HL. The need for more effcient trial designs. Stat Med. 2006;25:3231–3235.CrossRefGoogle Scholar
  8. 8.
    Jennison C, Turnbull BW. Effcient group sequential designs when there are several effect sizes under consideration. Stat Med. 2006;25: 917–932.CrossRefGoogle Scholar
  9. 9.
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Rahway, NJ: Erlbaum; 1988.Google Scholar
  10. 10.
    Make B. How can we assess outcomes of clinical trials: the MCID approach. J Chron Obstruct Pulm-on Dis. 2007;4:191–194.CrossRefGoogle Scholar
  11. 11.
    Sierevelt IN, Oldenrijk J, Poolman RW. Is statistical significance clinically important? A guide to judge the clinical relevance of study fndings. J Long-Term Effects Med Implants. 2007;17(2):173–179.CrossRefGoogle Scholar
  12. 12.
    Farrar JT, Young J P, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;149–158.Google Scholar
  13. 13.
    Burback D, Molnar FJ, John PS, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10:534–540.CrossRefGoogle Scholar
  14. 14.
    Man-Son-Hing M, Laupacis A, O’Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med. 2002;17:469–476.CrossRefGoogle Scholar

Copyright information

© Drug Information Association, Inc 2011

Authors and Affiliations

  • Kanae Togo
    • 1
    Email author
  • Nobushige Matsuoka
    • 1
  • Satoshi Hashigaki
    • 1
  • Keiji Imai
    • 1
  • Takashi Moriya
    • 1
  1. 1.Clinical StatisticsPfizer Japan IncYoyogi, Shibuya-ku TokyoJapan

Personalised recommendations